Market Dynamics of Authorized Generics in Medicaid from 2014 to 2020.

AGs represented a small share of Medicaid prescription drug use from 2014-2020, but when AGs were available, they accounted for sizeable market share. Among the minority of cases in which AGs were marketed a year or more before independent generics, manufacturers may be using AGs to bolster brand-name drug prices or to undermine independent generic competition, meriting further attention by regulators.